866-997-4948(US-Canada Toll Free)

Seroquel Analysis and Estimates from 2002 to 2020

Published By :

GlobalData

Published Date : Jul 2011

Category :

Therapeutic Area

No. of Pages : 32 Pages


GlobalDatas pharmaceuticals report, Seroquel Analysis and Estimates from 2002 to 2020 provides Seroquel sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Schizophrenia market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. 

Scope
  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Seroquel including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Seroquel including efficacy, safety, pricing and other details which influence its sales potential
  • Detailed sales forecast for 2011-2020 for Seroquel in each of the seven major markets
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 4
2.1 Schizophrenia 4
2.2 Symptoms 4
2.3 Schizophrenia Market 4
2.4 Epidemiology 4
2.5 Etiology 5
2.5.1 Genetic Factors 5
2.5.2 Environmental Factors 5
2.5.3 Abnormal Brain Structure 6
2.6 GlobalData Report Guidance 6

3 Schizophrenia: Market Characterization 7
3.1 Schizophrenia Market 7
3.2 Schizophrenia Market Forecasts and CAGR 7
3.3 Drivers of Schizophrenia Therapeutics Market 8
3.3.1 Patent Expiry of Leading Marketed Drugs 8
3.3.2 Increasing Patient Pool 8
3.3.3 High Prescription Rates 8
3.3.4 Low Patient Compliance Rate 8
3.3.5 High Unmet Need 8

4 Classification of Schizophrenia 9
4.1 Age of Onset of Schizophrenia 9
4.1.1 Pediatric / Adolescent / Childhood Schizophrenia 9
4.1.2 Adult Schizophrenia 10
4.2 Associated Symptoms 10
4.2.1 Paranoid Schizophrenia 10
4.2.2 Disorganized Schizophrenia 10
4.2.3 Catatonic Schizophrenia 10
4.2.4 Residual Schizophrenia 10
4.2.5 Undifferentiated Disorder 10

5 Treatment for Schizophrenia 11
5.1 Crisis Resolution Teams (CRT) 11
5.2 Voluntary and Compulsory Detention 11
5.3 Antipsychotics 11
5.3.1 Typical Antipsychotics 11
5.3.2 Atypical Antipsychotics 12
5.3.3 Increased Mortality in Elderly Patients with Dementia-Related Psychosis 12

6 Seroquel 13
6.1 Introduction 13
6.2 Mechanism of Action 13
6.3 Clinical Studies 13
6.3.1 Phase III Study Assessing Efficacy and Tolerability of Seroquel in Patients who Experienced an Inadequate Response to or Intolerance to their Prior Antipsychotic Treatment 13
6.3.2 Clinical Antipsychotic Trials for Intervention Effectiveness (CATIE) Schizophrenia Trial 14
6.4 Factors Affecting Sales of Seroquel 15
6.4.1 Patent Expiry of Seroquel and Other Competing Drugs 15
6.4.2 Safety Labeling Changes of Seroquel 15
6.4.3 CATIE Study Results 15
6.4.4 Increasing Patient Pool 15
6.5 Drug Evaluation 15
6.5.1 Drug Risk Benefit Score 15
6.5.2 Intensity of Competition 16
6.6 Sales Forecasts 18
6.6.1 Target Patient Pool of Seroquel 18
6.6.2 Dosing 18
6.6.3 Market Penetration 18
6.6.4 Annual Cost of Therapy 19
6.6.5 Sales Projections of Seroquel 20

7 Schizophrenia Market: Appendix 29
7.1 Market Definitions 29
7.2 Abbreviations 29
7.3 Research Methodology 29
7.4 Drug Sales Estimates Model 31
7.5 Contact Us 31
7.6 Disclaimer 32
7.7 Sources 32

List of Table


Table 1: CATIE Schizophrenia Trial Results 14
Table 2: Drug Risk Benefit Score of Seroquel 16
Table 3: Competitors of Seroquel 17
Table 4: Seroquel, Annual Treatment Costs for Schizophrenia, Global, 2010 19
Table 5: Seroquel, Schizophrenia, Global, Sales Estimates ($m), 20022010 20
Table 6: Seroquel, Schizophrenia, Global, Sales Estimates ($m), 20022010 20
Table 7: Seroquel, Schizophrenia, The US, Sales Estimates ($m), 20022010 21
Table 8: Seroquel, Schizophrenia, The US, Sales Forecasts ($m), 20112016 21
Table 9: Seroquel, Schizophrenia, The UK, Sales Estimates ($m), 20022010 22
Table 10: Seroquel, Schizophrenia, The UK, Sales Forecasts ($m), 20112016 22
Table 11: Seroquel, Schizophrenia, France, Sales Estimates ($m), 20022010 23
Table 12: Seroquel, Schizophrenia, France, Sales Forecasts ($m), 20112016 23
Table 13: Seroquel, Schizophrenia, Germany, Sales Estimates ($m), 20022010 24
Table 14: Seroquel, Schizophrenia, Germany, Sales Forecasts ($m), 20112016 24
Table 15: Seroquel, Schizophrenia, Italy, Sales Estimates ($m), 20022010 25
Table 16: Seroquel, Schizophrenia, Italy, Sales Forecasts ($m), 20112016 25
Table 17: Seroquel, Schizophrenia, Spain, Sales Estimates ($m), 20022010 26
Table 18: Seroquel, Schizophrenia, Spain, Sales Forecasts ($m), 20112016 26
Table 19: Seroquel, Schizophrenia, Japan, Sales Estimates ($m), 20022010 27
Table 20: Seroquel, Schizophrenia, Japan, Sales Forecasts ($m), 20112016 27

List of Chart


Figure 1: Risk of Developing Schizophrenia 5
Figure 2: Environmental Factors in the Development of Schizophrenia 6
Figure 3: Schizophrenia, Global, Market Size Forecasts ($bn), 20102020 7
Figure 4: Classification of Schizophrenia based on the Age of Disease Onset 9
Figure 5: Reduction in PANSS Scores for Atypical Antipsychotics 17
Figure 6: Drug Model Diagram of Seroquel 18
Figure 7: Seroquel, Schizophrenia, Global, Sales Estimates($m), 20022016 20
Figure 8: Seroquel, Schizophrenia, The US, Sales Estimates($m), 20022016 21
Figure 9: Seroquel, Schizophrenia, The UK, Sales Estimates($m), 20022016 22
Figure 10: Seroquel, Schizophrenia, France, Sales Estimates($m), 20022016 23
Figure 11: Seroquel, Schizophrenia, Germany, Sales Estimates($m), 20022016 24
Figure 12: Seroquel, Schizophrenia, Italy, Sales Estimates($m), 20022016 25
Figure 13: Seroquel, Schizophrenia, Spain, Sales Estimates($m), 20022016 26
Figure 14: Seroquel, Schizophrenia, Japan, Sales Estimates($m), 20022016 27
Figure 15: Seroquel, Schizophrenia, Global, Sales Distribution (%), 2011 28

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *